Hypertension Management Algorithm
Start lifestyle modifications immediately for all patients with BP ≥120/70 mmHg, and initiate pharmacotherapy at BP ≥130/80 mmHg for high-risk patients (CVD, CKD, diabetes, or 10-year CVD risk ≥7.5%) or at BP ≥140/90 mmHg for all others, targeting <130/80 mmHg in most patients. 1
Blood Pressure Classification and Diagnosis
Measurement Protocol:
- Use validated automated upper arm cuff device with appropriate cuff size
- Measure BP in both arms at first visit; use the arm with higher reading
- Confirm hypertension with home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) 2, 1
BP Categories:
- Normal: <120/80 mmHg → Remeasure in 3 years
- Elevated: 120-129/<80 mmHg → Lifestyle modifications
- Stage 1 Hypertension: 130-139/80-89 mmHg → Risk-stratified treatment
- Stage 2 Hypertension: ≥140/90 mmHg → Immediate dual therapy 1
Treatment Initiation Algorithm
For BP ≥140/90 mmHg (Stage 2):
- Immediately start: Lifestyle modifications + dual pharmacotherapy (single-pill combination preferred) 1
- No waiting period required
For BP 130-139/80-89 mmHg (Stage 1):
High-Risk Patients (start medications immediately):
- Clinical CVD (coronary disease, heart failure, stroke)
- Diabetes mellitus
- Chronic kidney disease
- 10-year CVD risk ≥7.5% by PREVENT calculator
- Age 50-80 years with any of above 2, 1
Lower-Risk Patients:
- Trial lifestyle modifications for 3-6 months
- If BP remains ≥130/80 mmHg after trial, initiate pharmacotherapy 1
For BP 120-129/<80 mmHg (Elevated):
- Lifestyle modifications only
- Reassess in 3-6 months 1
Pharmacotherapy Algorithm
Initial Drug Selection
For Stage 2 Hypertension (≥140/90 mmHg): Start with two first-line agents in single-pill combination 1
Non-Black Patients - Sequential Steps:
- Low-dose ACE inhibitor or ARB (start here for monotherapy if Stage 1)
- Add DHP calcium channel blocker
- Increase both to full doses
- Add thiazide or thiazide-like diuretic
- Add spironolactone (or if not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker) 2
Black Patients - Sequential Steps:
- Low-dose ARB + DHP calcium channel blocker OR DHP calcium channel blocker + thiazide/thiazide-like diuretic
- Increase to full doses
- Add diuretic (if not already included) or ACE inhibitor/ARB
- Add spironolactone (or alternatives as above) 2, 3
Key Principle: Simplify regimen with once-daily dosing and single-pill combinations to improve adherence 2
Special Populations
Diabetes or CKD:
- Prefer ACE inhibitor or ARB as initial therapy
- Target <130/80 mmHg 4, 3
- Monitor renal function and potassium within 3 months, then every 6 months 4
Heart Failure with Reduced Ejection Fraction:
- ACE inhibitor/ARB (or ARNI) + beta-blocker + MRA + SGLT2 inhibitor + diuretic as needed 3
Elderly (>80 years) or Frail:
- Consider monotherapy initially
- Individualize targets based on frailty
- May accept higher targets (e.g., <140/90 mmHg) 2
Blood Pressure Targets
Standard Target for Most Patients: <130/80 mmHg 2, 1
Consider More Intensive Target (<120 mmHg systolic):
Individualized Targets:
- Frail elderly: May target <140/90 mmHg
- Age >85 years: Individualize based on tolerability
- CKD with eGFR >30: Consider 120-129 mmHg if tolerated 3
Achieve target within 3 months of treatment initiation 2
Lifestyle Modifications (S-ABCDE Framework)
Implement for all patients with BP ≥120/70 mmHg:
- Sodium restriction: <2000 mg/day
- Alcohol moderation: ≤2 drinks/day men, ≤1 drink/day women
- Body weight: Reduce by 5-10% if overweight (BMI ≥25)
- Cigarette smoking cessation
- DASH diet: Emphasize fruits, vegetables, low-fat dairy, reduced saturated fat
- Exercise: 150 minutes/week moderate-intensity aerobic activity 1, 5
Additional: Increase dietary potassium, stress management, consider potassium-based salt substitutes 1
Resistant Hypertension Management
Definition: BP remains ≥130/80 mmHg despite 3 appropriately dosed medications including a diuretic
Management Steps:
- Verify adherence and proper BP measurement technique
- Screen for secondary causes, especially primary aldosteronism (regardless of potassium level) 1
- Reinforce lifestyle modifications, especially sodium restriction
- Add spironolactone 25-50 mg daily (first-line for resistant hypertension) 3
- If spironolactone not tolerated: eplerenone, amiloride, higher-dose thiazide, or loop diuretic
- Consider adding: bisoprolol, doxazosin, or centrally-acting agent 3
- Refer to hypertension specialist if still uncontrolled 2
Renal denervation may be considered at high-volume centers after multidisciplinary assessment and shared decision-making 3
Monitoring Protocol
Initial Phase (First 3 months):
- Assess BP control monthly
- Adjust medications to reach target within 3 months
- Monitor for adverse effects, adherence 2
Maintenance Phase:
- Home BP monitoring: Duplicate readings, twice daily, over 7 consecutive days (722 protocol)
- Office visits every 3-6 months once controlled
- Annual assessment of target organ damage (urinary albumin-to-creatinine ratio, ECG/echo if indicated) 1
Laboratory Monitoring:
- Baseline: Creatinine, eGFR, potassium, urinary albumin-to-creatinine ratio
- Repeat within 2-4 weeks after starting/adjusting ACE inhibitor, ARB, or diuretic
- Then every 6-12 months if stable 4
Critical Pitfalls to Avoid
- Do not rely on single office readings - confirm with home or ambulatory monitoring 2
- Do not delay treatment in Stage 2 hypertension - start dual therapy immediately 1
- Do not use race to guide initial drug selection - evidence does not support this practice in 2025 guidelines 1
- Do not accept "white coat effect" without confirmation - verify with out-of-office measurements
- Do not screen for primary aldosteronism only when potassium is low - screen all resistant hypertension patients 1
- Do not use cuffless devices or smartwatches for clinical BP management until validated 1
- Do not treat severe hypertension (>180/120 mmHg) without acute organ damage in the emergency department - manage in outpatient setting with oral medications 1